OCSY .0002 NEWS Marketing Strategy All Content and

New Post Public Reply Private Reply Replies (0) Message Board
FLA
227
OCSY .0002 NEWS Marketing Strategy


All Content and Data provided by Third-Parties — Terms of Use
Optium Cyber Systems Reveals Marketing Strategy for Monetization of Cyber Security Platform for Medical Sector
MARKET WIRE 7:30 AM ET 11/21/2017
Symbol Last Price Change
OCSY 0.0002down 0 (0%)
QUOTES AS OF 03:34:41 PM ET 11/20/2017
THE WOODLANDS, TX -- (Marketwired) -- 11/21/17 -- Optium Cyber Systems, Inc.(OCSY) (the Company) today released for its shareholders the marketing strategy for the monetization of its leading edge cyber security platform developed for the medical sector.

The initial rollout will focus on marketing to health care networks in the Greater Houston area which is made up of over 40+ hospitals. Each facility represents $20,000 per initial Cyber Vulnerability Assessment (CVA) and then monthly recurring revenue of $15,000 - $25,000. The marketing efforts will initially rely heavily on the associations and affiliations of the Company's Board of Advisors and then continue to grow through aggressive marketing and development of strategic alliances. The Company will be presenting to a number of the key decision makers of these networks in the very near future with the main message of highlighting the results of its first CVA and the potential catastrophic losses a cyber breach can cause including the financial liability for the institution and its directors.

"As I previously stated, hospital executives and board members cannot bury their heads in the sand and ignore the threat of a cyber breach. They must be made aware of the potential losses a cyber breach represents and take the necessary steps to protect their institution and their patients," stated Michael T. Rutherford, CEO of Optium Cyber Systems(OCSY). "They must be proactive and address the threat of a cyber infiltration. The first step in this process is to identify the vulnerabilities in their IT environment by performing a CVA," continued Mr. Rutherford.

"The results of our first CVAs speak for themselves. Directors and decisions making the decisions need to realize the need to take note that our platform delivers on its promise," stated George M. Rutherford, President of Optium Cyber Systems(OCSY). "Ignoring the threat of a cyber breach not only put patients in harm's way but also opens the door to financial damages to institution and key decision makers," continued Mr. Rutherford., "We are now in the position that we should become exponential in our growth with a proven product such as OCSI has presented into the market".

"For years we have had studies put out by industry experts related to the Health Insurance Portability and Accountability Act's security rules, but now we have a comprehensive Healthcare Cyber Vulnerability Assessment specifically designed to help protect hospitals from cyber criminals. Executives and decision makers of these facilities should sit up and take notice," commented Mr. Mark R. Anderson, a former Chief Information Officer with 5 multi-Hospital Chains and a current member of the Board of Advisors for Optium Cyber Systems, Inc.(OCSY)

About Optium Cyber Systems, Inc.(OCSY)
OCSI has developed a proprietary process to analyze, identify and address cyber security vulnerabilities in an organization's critical IT infrastructure which is scalable to any size organization in any industry. OCSI has recently launched in the health care sector, focusing on protecting health care facilities including hospitals, nursing homes and doctor's offices from cyberthreats such as the manipulation of medical devices or theft of patient records. OCSI is a publicly traded company having its common shares quoted on the OTC Markets under the symbol "OCSY".

Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See Optium Cyber Systems, Inc.'s filings with OTC Markets which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact
Investor Relations
Ten Associates LLC
11529 N. 120th St.
Scottsdale, Arizona
85259 USA
Telephone: 480-326-8577
Contact: Thomas E. Nelson
Email: tenassociates33@gmail.com

Optium Cyber Systems, Inc.(OCSY)
8350 Ashlane Way, Suite 104
The Woodlands, Texas
77382 USA
Telephone: 936-559-7407
Web: www.optiumcyber.com
Email: info@optiumcyber.com
Twitter: https://twitter.com/OCSI4INVESTOR
Facebook: https://www.facebook.com/OCSI4INVESTOR

Source: Optium Cyber Systems, Inc.(OCSY)
I ONLY POST WHAT I PLAY
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Promising Interim Findings from Medicus Pharma's BCC Study

Updated Category News Views 164

Positive Interim Analysis from Medicus Pharma Ltd Medicus Pharma Ltd. (NASDAQ: MDCX) has recently shared exciting interim results from its SKNJCT-003 Phase 2 clinical study, which focuses on a non-invasive approach to treat basal cell carcinoma (BCC) of the skin. This news marks a significant milestone as the company aims to revolutionize the treatment options available...

Continue Reading
DroneShield's Immediate Response Kit Wins Platinum Award for Innovation

Updated Category News Views 161

DroneShield's Immediate Response Kit Gains Recognition for Innovation DroneShield has recently been awarded the prestigious Platinum Award for Innovation by Military and Aerospace Electronics, showcasing its Immediate Response Kit (IRK) as a cornerstone in drone detection and defeat technology. This award is a testament to the exceptional capabilities of the IRK, which...

Continue Reading
Jefferies Holds ABB Rating; Analysts Assess Mixed Results

Updated Category News Views 65

Jefferies Maintains Hold Rating on ABB Stock Jefferies recently continued its Hold rating for ABB Ltd (NYSE: ABB) and set a price target of CHF50.00, following the company's third-quarter performance report. The report showcased a mixed array of results, with certain metrics outperforming expectations while others showed disappointing trends. During the third quarter, ABB...

Continue Reading
Surgical Clips Market Projected to Reach $1.8 Billion Soon

Updated Category News Views 211

Overview of the Surgical Clips Market Recent analysis of the surgical clips market reveals an impressive valuation of USD 655.9 million in 2023, with projections indicating a potential growth to USD 1.8 billion by 2032. This remarkable increase is attributed to a compound annual growth rate (CAGR) of 11.9% from 2024. Understanding Surgical Clips and Their Importance...

Continue Reading
Public Disclosure of Opening Position by Keywords Studios Plc

Updated Category News Views 74

Public Opening Position Disclosure for Keywords Studios Plc This document provides important information about a public opening position disclosure related to Keywords Studios Plc. It includes details about individuals or entities holding 1% or more of relevant securities. This disclosure is made in accordance with Rule 8.3 of the Takeover Code, which ensures that all...

Continue Reading